• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Envista Holdings Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/21/26 4:24:18 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email
    nvst-20260519
    0001757073FALSE00017570732026-05-192026-05-19

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________________
    FORM 8-K
    _____________________________________________
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of report (Date of earliest event reported): May 19, 2026
    _____________________________________________
    envistalogoa26.jpg
    ENVISTA HOLDINGS CORPORATION
    (Exact Name of Registrant as Specified in Its Charter)
    _____________________________________________
    Delaware
    (State or Other Jurisdiction of Incorporation)
    001-3905483-2206728
    (Commission File Number)(IRS Employer Identification No.)
    200 S. Kraemer Blvd., Building E92821
    Brea,California
    (Address of Principal Executive Offices)(Zip Code)
    (714) 817-7000
    (Registrant’s Telephone Number, Including Area Code)
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)
    _____________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock, $0.01 par value NVST New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company      ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐





    ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

    On May 19, 2026, Envista Holdings Corporation, (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following proposals:

    Proposal 1- Election of Directors

    The Company’s stockholders elected the persons listed below as Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until his or her successor is elected and qualified by the following votes:
    NomineeVotes ForVotes WithheldBroker Non-Votes
    Wendy Carruthers147,946,4021,746,6723,975,452
    Kieran Gallahue145,760,5703,932,5043,975,452
    Scott Huennekens146,084,5243,608,5503,975,452
    Vivek Jain148,147,8901,545,1843,975,452
    Paul Keel149,459,395233,6793,975,452
    J. Andrew Pierce149,001,825691,2493,975,452
    Daniel Raskas146,750,9102,942,1643,975,452
    Christine Tsingos147,739,5271,953,5473,975,452

    Proposal 2 - Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accountant

    To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The proposal was approved by a vote of stockholders as follows:

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    152,689,635913,16165,730—

    Proposal 3 - Advisory Vote to Approve Executive Compensation

    To approve on an advisory basis the Company’s named executive officer compensation. The proposal was approved by a vote of stockholders as follows: 

    Votes ForVotes AgainstVotes AbstainedBroker Non-Votes
    144,475,2425,144,79873,0343,975,452

    Proposal 4 - Advisory Vote on Frequency of Future Advisory Votes on Named Executive Officer Compensation

    To hold an advisory vote relating to the frequency of future shareholder advisory votes on the Company’s named executive officer compensation. The Company’s shareholders voted as follows on this proposal:

    One YearTwo YearsThree YearsVotes AbstainedBroker Non-Votes
    139,798,4636,1509,840,87847,5833,975,452

    Based on the voting results set forth above, the Company has adopted a policy to hold an annual advisory vote on named executive officer compensation until the next required vote on the frequency of shareholder advisory votes on the Company’s named executive officer compensation.
    ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
    (d) Exhibits.



    Exhibit No. Description
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     ENVISTA HOLDINGS CORPORATION
       
       
    Date: May 21, 2026By:/s/ Mark Nance
      Mark Nance
      Senior Vice President, General Counsel and Secretary


    Get the next $NVST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    4/15/2026$29.00Neutral
    Citigroup
    2/6/2026$35.00Market Perform → Outperform
    Leerink Partners
    12/9/2025$24.00Overweight
    Barclays
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,811 shares, decreasing direct ownership by 3% to 371,574 units (SEC Form 4) to satisfy tax liability

    4 - Envista Holdings Corp (0001757073) (Issuer)

    5/27/26 4:17:15 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Director Tsingos Christine A was granted 9,330 shares, increasing direct ownership by 18% to 59,930 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    5/21/26 4:37:24 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Director Carruthers Wendy was granted 9,330 shares, increasing direct ownership by 18% to 59,940 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    5/21/26 4:37:30 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14

    5/22/26 8:00:00 AM ET
    $DHR
    $HSIC
    $NVST
    Industrial Machinery/Components
    Industrials
    Medical Specialities
    Health Care

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    Envista Schedules First Quarter 2026 Earnings Call

    BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2026 on Wednesday, May 6, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can

    4/8/26 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/14/24 4:40:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/13/24 6:01:10 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    11/20/23 5:49:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Envista with a new price target

    Citigroup initiated coverage of Envista with a rating of Neutral and set a new price target of $29.00

    4/15/26 8:08:24 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Market Perform to Outperform and set a new price target of $35.00

    2/6/26 8:05:48 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Envista with a new price target

    Barclays initiated coverage of Envista with a rating of Overweight and set a new price target of $24.00

    12/9/25 8:46:01 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    SEC Filings

    View All

    Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Envista Holdings Corp (0001757073) (Filer)

    6/3/26 4:54:52 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Envista Holdings Corporation

    SD - Envista Holdings Corp (0001757073) (Filer)

    5/28/26 5:19:22 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Holdings Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Envista Holdings Corp (0001757073) (Filer)

    5/21/26 4:24:18 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Financials

    Live finance-specific insights

    View All

    Envista Schedules First Quarter 2026 Earnings Call

    BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2026 on Wednesday, May 6, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can

    4/8/26 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Reports Fourth Quarter 2025 Results

    BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2025. "With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista," said Paul Keel, CEO.  "We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025.  In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee d

    2/5/26 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Fourth Quarter 2025 Earnings Call

    BREA, Calif., Jan. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2025 on Thursday, February 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y

    1/8/26 4:20:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Paul Keel to its Board of Directors

    SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient

    5/4/26 4:15:00 PM ET
    $COO
    $NVST
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Compass Diversified Announces Stephen Keller as Chief Financial Officer

    WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

    8/26/24 6:00:00 AM ET
    $AVY
    $CODI
    $NVST
    Containers/Packaging
    Consumer Discretionary
    Home Furnishings
    Medical/Dental Instruments

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    11/8/24 12:09:03 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    2/14/24 4:08:38 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care